期刊文献+

表观遗传学调控与妇科肿瘤发生、演进及治疗的研究进展 被引量:7

Progression of epigenetic changes in human ovarian cancer,endometrial cancer and cervical cancer
下载PDF
导出
摘要 在卵巢肿瘤、子宫内膜癌以及宫颈癌中,已有许多研究证明了遗传学和表观遗传学修饰对肿瘤发生、发展的影响。以往研究证实癌基因、抑癌基因以及细胞信号传导通路异常导致肿瘤形成。与基因突变不同的是,表观遗传学并不是通过改变基因组序列,而是通过甲基化修饰、组蛋白修饰、miRNA调节等方式对基因组进行调控。甲基化异常、组蛋白修饰错误或miRNA调控紊乱与肿瘤细胞增殖、自噬、凋亡、细胞间粘附、浸润和转移密切相关。表观遗传学修饰作为肿瘤发生发展的关键因素,将其作为靶点应用于诊断治疗及评估预后将是重要的研究方向。 Multiple genetic and epigenetic changes have been studied in ovarian cancer,endometrial cancer and cervical cancer,however,such changes are selected for during tumorigenesis and tumor aggression is not yet clear.The epigenetic changes of oncogenes,tumor suppressor genes and abnormal signaling pathways cause tumorigenesis.Aberrations epigenetic regulation in cell proliferation,apoptosis,autophagy and changes in cell adhesion and motility all contribute to disease development and metastasis.In contrast to genetic mutations,epigenetic events lead to changes in gene expression other than by means of DNA sequence alteration including DNA methylation,histone modifications and microRNA dysregulation.From what is presently known,epigenetics are more and more important in the development and progression of ovarian cancer,endometrial cancer and cervical cancer.
出处 《临床肿瘤学杂志》 CAS 2012年第1期74-80,共7页 Chinese Clinical Oncology
基金 国家自然科学基金资助项目(30872760) 上海市科委基金资助项目(10JC1415600)1
关键词 表观遗传学 卵巢肿瘤 子宫内膜癌 宫颈癌 甲基化 组蛋白 MIRNA Epigenetics Ovarian tumor Endometrial carcinoma Cervical carcinoma Methylation Histones miRNA
  • 相关文献

参考文献32

  • 1Castilla MA, Moreno-Bueno G, Romero-Perez L, et al. Micro- RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma[ J]. J Pathol,2011,223 ( 1 ) : 72 - 80.
  • 2Tsou JA, Hagen JA, Carpenter CL. DNA methylation analysis: a powerful new tool for lung cancer diagnosis [ J ]. Oncogene, 2002,21 (35) :5450 -5461.
  • 3Vivek Shukla,Xavier Coumoul,Tyler Lahusen,Rui-Hong Wang,Xiaoling Xu,Athanassios Vassilopoulos,Cuiying Xiao,Mi-Hye Lee,Yan-Gao Man,Mutsuko Ouchi,Toru Ouchi,Chu-Xia Deng.BRCA1 affects global DNA methylation through regulation of DNMT1[J].Cell Research,2010,20(11):1201-1215. 被引量:5
  • 4Suzuki H, Gabrielson E, Chen W, et aI. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer [J]. Nat Genet, 2002,31 (2) : 141 -149.
  • 5Shi H, Yan PS, Chen CM, et aI. Expressed CpG island sequence tag microarray for dual screening of DNA hypermethylation and gene silencing in cancer cells [J]. Cancer Res, 2002, 62 (II) :3214 - 3220.
  • 6Bartel DP. MicroRNAs: target recognition and regulatory functions[J]. Cell,2009,136(2) :215 -233.
  • 7Martello G,Rosato A, Ferrari F ,et al. A microRNA targeting dieer for metastasis control [J]. Cell, 20 10 , 141 (7) : 1195 - 1207.
  • 8Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation [J]. Nat Rev Cancer, 2009 ,9 (6) :415 -428.
  • 9Balch C, Fang F, Matei DE,et al. Minireview , epigenetic changes in ovarian cancer[J]. Endocrinology, 2009 ,ISO (9) :4003 - 4011.
  • 10Press jz, De Luca A, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCAI loss have distinct molecular abnormalities[J]. BMC Cancer, 2008,8(1) : 17.

二级参考文献62

  • 1Robertson KD, Jones PA. DNA methylation: past, present and future directions. Carcinogenesis 2000; 21:461-467.
  • 2Agrawal A, Murphy R_F, Agrawal DK. DNA methylation in breast and colorectal cancers. ModPatho12007; 20:711-721.
  • 3Siedlecki P, Zielenkiewicz P. Mammalian DNA methyltransferases. Acta Biochim Pol 2006; 53:245-256.
  • 4Lafon-Hughes L, Di Tomaso MV, Mendez-Acuna L, Martinez-Lopez W. Chromatin-remodelling mechanisms in cancer. Mutat Res 2008; 658:191-214.
  • 5Esteller M. Cancer epigenetics: DNA methylation and chromatin alterations in human cancer. Adv Exp Med Biol 2003; 532:39-49.
  • 6Soares J, Pinto AE, Cunha CV, et aL Global DNA hypomethylation in breast carcinoma: correlation with prognostic factors and tumor progression. Cancer 1999; 85:112-118.
  • 7Jackson K, Yu MC, Arakawa K, et al. DNA hypomethylation is prevalent even in low-grade breast cancers. Cancer Biol Ther 2004; 3:1225-1231.
  • 8Jeltsch A. Molecular enzymology of mammalian DNA methyltransferases. Curr Top Microbiol Immunol 2006; 301:203- 225.
  • 9Bonfini L, Karlovich CA, Dasgupta C, Banerjee U. The son of sevenless gene product: a putative activator of Ras. Science 1992; 255:603-606.
  • 10Gonzalo S, Jaco I, Fraga MF, et al. DNA methyltransferases control telomere length and telomere recombination in mammalian cells. Nat Cell Biol 2006; 8:416-424.

共引文献4

同被引文献110

  • 1任琳琳,房静远.肿瘤中自噬的表观遗传学研究进展[J].中国癌症杂志,2011,21(6):484-488. 被引量:2
  • 2王金桃,马晓晨,程玉英,丁玲,周芩.叶酸与宫颈癌关系的病例对照研究[J].中华流行病学杂志,2006,27(5):424-427. 被引量:31
  • 3徐卫,李建勇,陆凤翔.微小RNA及其在恶性淋巴增殖性疾病中作用的研究进展[J].中国实验血液学杂志,2006,14(4):840-844. 被引量:4
  • 4郑莹,彭芝兰,楼江燕,王和.宫颈癌及癌前病变HPV-16存在状态检测的研究[J].中国肿瘤临床,2006,33(17):961-965. 被引量:10
  • 5Prislei S, Martinelli E, Mariani M, et al. MiR-200c and HuR in ovarian cancer [J]. BMC Cancer, 2013, 13:72.
  • 6Suryawanshi S, Vlad AM, Lin HM, et al. Plasma MicroRNAs as Novel Biomarkers for Endometriosis and Endometriosis-Associatcd Ovarian Cancer [J]. Clin Cancer Res, 2013, 19(5): 1213-1224.
  • 7Kau CW, Hahn MA, Gard GB, et al. Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer [J]. BMC Cancer, 2012, 12: 627.
  • 8Jemal A,Siegel R,Ward E,et al.Cancer statistics,2009[J].CA Cancer J Clin,2009,59(4):225-249.
  • 9Spector,Tim.Identically Different:Why You Can Change Your Genes[M].London:Weidenfeld&Nicolson,2012:8.
  • 10Matsumura N,Huang Z,Mori S,et al.Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer[J].Genome Res,2011,21(1):74-82.

引证文献7

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部